Klinicheskiy sluchay: primenenie selektivnogo antagonistaretseptorov endotelina ambrizentana pri idiopaticheskoy legochnoy gipertenzii

Authors: Andreeva Y.A¹, Martynyuk TV¹, Ataullakhanova DM¹, Lazutkina VK¹, Korobkova IZ¹, Sakhnova TA¹, Blinova EV¹, Danilov NM¹, Nakonechnikov SN¹, Chazova IE¹
Affiliations:
Issue: Vol 5, No 1 (2008)
Pages: 57-64
Section: Articles
URL: https://journals.eco-vector.com/2075-082X/article/view/28812
DOI: https://doi.org/10.26442/SG28812
ID: 28812

Cite item

Full Text

Беленков Ю.Н., Чазова И.Е. Первичная легочная гипертензия. М.: Нолидж, 1999.
Диагностика и лечение легочной гипертензии. Российские рекомендации ВНОК. М., 2007.
Rubin et al. Bosentan: a dual endothelin receptor antagonist. Expert Opin Investig Drugs 2002; 11: 991
Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004; 351: 1425-36.
Clozel M. Endothelin receptor antagonists: current status and perspectives. J Cardiovasc Pharmacol 2000; 35: S65.
Gali_ N, Badesch D, Oudiz R et al. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2005; 46 (3): 529-35.
Battistini B, Berthiaume N, Kelland NF et al. Profile of past and current clinical trials involving endothelin receptor antagonists: the novel "-sentan" class of drug. Exp Biol Med (Maywood). 2006; 231 (6): 653-95.
Olschewski H, Galie N, Kramer M et al. Ambrisentan Improves Exercise Capacity and Time to Clinical Worsening in Patients with Pulmonary Arterial Hypertension: Results of the ARIES-2 Study. San Diego, CA: American Thoracic Society, 2006.

Supplementary Files

Action

1. JATS XML